Piramal Pharma Ltd vs Source Natural Foods Herbal Supplements Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Piramal Pharma Ltd is ₹ 161.9 as of 30 Apr 15:30 . The P/E Ratio of Piramal Pharma Ltd changed from 991.5 on March 2024 to 325.4 on March 2025 . This represents a CAGR of -42.71% over 2 yearsThe P/E Ratio of Source Natural Foods & Herbal Supplements Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Piramal Pharma Ltd changed from ₹ 8165 crore on March 2023 to ₹ 29763 crore on March 2025 . This represents a CAGR of 53.90% over 3 yearsThe Market Cap of Source Natural Foods & Herbal Supplements Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Piramal Pharma Ltd for the Mar '26 is ₹ 2811 crore as compare to the Dec '25 revenue of ₹ 2193 crore. This represent the growth of 28.18% The revenue of Source Natural Foods & Herbal Supplements Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Piramal Pharma Ltd for the Mar '26 is ₹ 344.37 crore as compare to the Dec '25 ebitda of ₹ 208.12 crore. This represent the growth of 65.47% The ebitda of Source Natural Foods & Herbal Supplements Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Piramal Pharma Ltd changed from ₹ -88.64 crore to ₹ -8.83 crore over 8 quarters. This represents a CAGR of -68.44% The net profit of Source Natural Foods & Herbal Supplements Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Piramal Pharma Ltd changed from 18.07 % on March 2022 to 2.68 % on March 2025 . This represents a CAGR of -37.94% over 4 yearsThe Dividend Payout of Source Natural Foods & Herbal Supplements Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Piramal Pharma Ltd

Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries.
It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India.
In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands.

About Source Natural Foods & Herbal Supplements Ltd

Source Natural Foods &Herbal Supplements Limited was formerly incorporated as Inwinex Pharmaceuticals Limited in 1995.
The Company name was then changed from Inwinex Pharmaceuticals Limited to Source Natural Foods &Herbal Supplements Limited in 2011-12.
The Company engages in the pharmaceutical business in India.
It provides allopathic and ayurvedic formulations.
Its principal products include Organic Ashwagandha, Organic Triphala, and Organic Satavari Tablets. Company operates in the Ayurveda and herbal sphere which has been identified as one of the key sectors of growth and innovation for the Country.

FAQs for the comparison of Piramal Pharma Ltd and Source Natural Foods & Herbal Supplements Ltd

Which company has a larger market capitalization, Piramal Pharma Ltd or Source Natural Foods & Herbal Supplements Ltd?

Market cap of Piramal Pharma Ltd is 21,520 Cr while Market cap of Source Natural Foods & Herbal Supplements Ltd is 81 Cr

What are the key factors driving the stock performance of Piramal Pharma Ltd and Source Natural Foods & Herbal Supplements Ltd?

The stock performance of Piramal Pharma Ltd and Source Natural Foods & Herbal Supplements Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Piramal Pharma Ltd and Source Natural Foods & Herbal Supplements Ltd?

As of May 4, 2026, the Piramal Pharma Ltd stock price is INR ₹161.9. On the other hand, Source Natural Foods & Herbal Supplements Ltd stock price is INR ₹127.3.

How do dividend payouts of Piramal Pharma Ltd and Source Natural Foods & Herbal Supplements Ltd compare?

To compare the dividend payouts of Piramal Pharma Ltd and Source Natural Foods & Herbal Supplements Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.